<DOC>
	<DOCNO>NCT01494311</DOCNO>
	<brief_summary>Arterial catheterization painful associate patient stress anxiety . Analgesia usually provide subcutaneous injection local anesthetic . An alternative topical anaesthesia , Rapydan novel topical anesthetic patch contain 70 mg lidocaine tetracaine . We therefore test hypothesis Rapydan patch analgesia non-inferior subcutaneous local anesthetic .</brief_summary>
	<brief_title>Rapydan Topical Anaesthesia Arterial Cannulation</brief_title>
	<detailed_description>Many clinical procedure include arterial venous puncture , percutaneous venous catheter insertion , lumbar puncture , dermatological procedure associate pain consequent patient discomfort.1-2 With exception venopuncture , arterial puncture common invasive procedure perform critically ill patient . Also , often necessary induction anaesthesia invasive measurement blood pressure collection arterial blood sample patient undergo major cardiac surgery . Injection local anesthetic insertion cause intra-dermal turgor trigger local vasoconstriction , reduce puncture success rate . An alternative approach use topical anesthesia percutaneous procedure . However , intact skin present significant barrier topical anesthetic preparation . Therefore , topical anesthetic preparation typically must apply occlusive dressing 45-60 minute vascular access â€” often longer clinically practical . Rapydan ( also know Synera United States ) novel topical anesthetic patch contain 70 mg lidocaine tetracaine . The central area Rapydan patch consist Controlled Heat Assisted Drug Delivery pod design allow application 20 minute percutaneous procedure . However , efficacy Rapydan topical analgesia yet quantify intense pain result arterial puncture . We thus compare routine analgesia ( subcutaneous injection 0.5 ml 1 % lidocaine ) heat lidocaine/tetracaine patch . Specifically , test hypothesis lidocaine/tetracaine patch analgesia non-inferior provide subcutaneous lidocaine injection insertion arterial catheter . Ninty patient undergo elective major cardiac surgery include prospective , double blind clinical trial . Patients randomly assign receive either lidocaine/tetracaine patch , follow subcutaneous injection 0.5 ml normal saline solution placebo patch , look identically Rapydan patch subsequent subcutaneous injection 0.5 ml lidocaine 1 % . Pain arterial catheterization use 100-mm-long visual analog scale ( VAS ) primary outcome . Other outcomes pain anesthetic/saline injection plasma tetracaine concentration . VAS pain score arterial puncture comparable group Rapydan non-inferior subcutaneous lidocaine . Pain score time subcutaneous injection significantly low ( well ) patient assign lidocaine/tetracaine patch lidocaine ( P = 0.001 ) . Plasma tetracaine concentration never exceed detection limit 25 ng/ml time patient . Both lidocaine/tetracaine patch subcutaneous injection lidocaine provide comparable pain control arterial catheter insertion . Subcutaneous lidocaine cause discomfort injection whereas lidocaine/tetracaine patch require placement 20 minute procedure . Given adequate time , patch provide well overall analgesia obviate need subcutaneous infiltration .</detailed_description>
	<mesh_term>Anesthetics</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<mesh_term>Tetracaine</mesh_term>
	<criteria>Patients elective valvereplacement coronary artery bypass graft require arterial access induction anaesthesia . analgesic use within 24 hour surgery injury infection plan puncture site know allergy local anesthetic drug abuse alcoholism psychiatric disorder childbearing potential without adequate birth control abnormal Allen 's test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Arterial catheter</keyword>
	<keyword>arterial cannula</keyword>
	<keyword>Rapydan</keyword>
	<keyword>lidocaine/tetracaine patch</keyword>
	<keyword>topical anaesthesia</keyword>
</DOC>